Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 4 of 4.

Slides:



Advertisements
Similar presentations
Dr. Chris Cobourn Medical Director and Surgeon Surgical Weight Loss Centre Staff Surgeon Trillium Health Centre Mississauga, Ontario.
Advertisements

Type 2 diabetes Years from diagnosis Pre-diabetes Onset Diagnosis Insulin secretion Insulin “efficiency” Ramlo-Halsted BA, Edelman SV.
Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.
Faculty Disclosure Mikayla Spangler, PharmD, BCPS Dr. Spangler has listed no financial interest/arrangement that would be considered a conflict of interest.
Diabetes in Pregnancy Screening.
Clinical Approaches to address the Obesity epidemic Ken Fujioka, M.D. Director of Nutrition and Metabolic Research Director of The Center for Weight Management.
Insulin initiation OPTIMISING Glycaemic control and Weight Dr C Rajeswaran Consultant Physician Diabetes & Endocrinology Mid Yorkshire NHS Trust.
Why Surgical Treatment of Diabetes May Not be a Good Option McGill First Canadian Summit on Surgery for Type 2 Diabetes Montréal, Québec May 7, 2010 David.
Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.
The Diagnosis of Diabetes Mellitus
Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon Daniel Bessesen, MD.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Jaime Ponce MD, FACS, FASMBS Director of Bariatric Surgery Hamilton Medical Center Dalton Georgia USA LAGB Weight Loss and Diabetes 2010 Minimally Invasive.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Obesity Surgery : Is it only for losing weight ? Joint Hospital Surgical Grand Round Simon Chu Prince of Wales Hospital.
Bariatric Surgery and Metabolism Goal: to review 4 important and clinically relevant papers from 2010 on Bariatric Surgery and Metabolism 10/10/20151.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.
Type 2 Diabetes – A Global Epidemic Arya M Sharma, MD, FRCP(C) Professor of Medicine Research Chair for Obesity Research & Management University of Alberta.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Toujeo® and it’s Place in Therapy
Type 1 Diabetes Treatment Options Stanley Schwartz Mark Stolar Emeritus, Univ of Pa Part 3.
GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
A Diabetes Outcome Progression Trial
Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 4 of 5.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 2 of 4.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.
Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 3 of 5.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.
Diabetes Update: Michael Gottschalk, M.D, Ph.D.
Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 2 of 5.
GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.
Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
GLP-1 agonists Ian Gallen Consultant Community Diabetologist
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach Part 1 1.
Hippocrates Prize Prof A. Kokkinos (Greece).
Key publication slides
Neal B, et al. Diabetes Care 2015;38:403–411
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Macrovascular Complications Microvascular Complications
Pramlintide Synthetic analog of the β-cell hormone amylin
GLP-1 Agonists and DPP-4 Inhibitors How do they work?
Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.
Section overview: Cardiometabolic risk reduction
Guidelines for Initiation of Therapy
Section overview: Cardiometabolic risk reduction
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.
Insulin Delivery Systems Atlanta Diabetes Associates
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.
Presentation transcript:

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 4 of 4

Amylin Insulin Amylin the Hormone 37-amino acid peptide Colocated and cosecreted with insulin from pancreatic  cells Deficient in diabetes Unger RH, et al. Williams Textbook of Endocrinology. 8th ed. 1992; Photographs reprinted with permission of Elsevier.

Pramlintide Synthetic analog of the  -cell hormone, amylin Pramlintide limits postprandial glucose excursions through at least 3 mechanisms of action – Slows gastric emptying – Decreases postprandial hypersecretion of glucagon – Increases satiety, leading to decreased caloric intake and potential weight loss Chapman I, et al. Diabetologia. 2005;48: Fineman M, et al. Horm Metab Res. 2002;34: Kong M-F, et al. Diabetologia. 1998;41: Kruger DF, et al. Drugs. 2004;64:

Effect of Pramlintide Adjunctive Therapy on Weight in Individuals With Type 2 Diabetes Placebo Weeks Change in Weight From Baseline (kg) * P<.05 vs placebo. Hollander PA, et al. Diabetes Care. 2003;26: Pramlintide [prescribing information]. Symlin® [package insert]. San Diego, CA: Amlyn Pharmaceuticals; 2007.

* * -0.3% ± 0.1 ∆ A1C (%) Time (weeks) † † † † † -2.3 ± 0. 4 kg ∆ Body Weight (kg) Placebo + Insulin Glargine Pramlintide + Insulin Glargine Baseline A1C 8.5 ± 0.1% Baseline Weight. 103 ± 1.8 kg 103 ± 1.7 kg Mean±SE; ITT LOCF: Placebo (n=106); Pramlintide (n=105); *P<.05 vs placebo; † P<.001 vs placebo. Riddle M, et al. Diabetes Care. 2007;30: Pramlintide Lowers A1C and Weight in Individuals With T2DM on Basal Insulin

Multihormonal Control of Body Weight: Role of Fat-, Gut-, and Islet-Derived Signals Leptin (r-met human) (AC164594) Pramlintide (AC137) PYY3-36 (synthetic) (AC162352) Clinical-Stage Compounds Adapted from Badman MK, et al. Science. 2005;307:

Weeks Leptin % ∆ Body Weight (vehicle corrected) Fen/phen 1 Roux-en-Y 2 Vehicle Amylin Amylin+Leptin ½ Dose: Amylin+Leptin+PYY 3-36 DIO = diet-induced obese; Continuous infusion of peptides at full doses (osmotic minipump). 1. Weintraub M, et al. Clin Pharmacol Ther. 1992;51(5): Stylopoulos N, et al. Surg Endosc. 2005;19: Roth JD, et al. Proc Natl Acad Sci U S A. 2008;105: Roth J, et al. Obesity. 2006;14(suppl 9):A57-A58. Abstract 177-P. Means of Achieving Greater Weight Loss: Integrated Therapy With 3 Neurohormones in DIO Rats

Bariatric Surgery: Gastrorestrictive Procedures Vertical-Banded Gastroplasty Gastric Bypass (Roux-en-Y) Gastric Banding Out of FavorGold StandardCommonly Used American Society for Bariatric Surgery. Accessed May 30, Mun EC, et al. Gastroenterology. 2001;120: Philadelphia, PA. Elsevier; 2003: Pratt JSA, et al. In: Office Management of Obesity.

Diabetes Remits After Adjustable Gastric Banding Unblinded, randomized, controlled trial of 60 individuals with type 2 diabetes diagnosed within preceding 2 years Diabetes remission defined by A1C <6.2%, taking no diabetes medications SurgeryControl P V alue Weight (kg)   5.4 <.001 A1C (%)   1.26 <.001 TG (mg/dL)   HDL-C (mg/dL) 12.6   6.1 <.001 % Achieving Remission of Diabetes Dixon JB, et al. JAMA. 2008;299: SurgeryConventional

Bariatric Surgery: Diabetes Compared to 2 year data, about half of those in remission after surgery will need treatment for diabetes at 10-year follow-up 1 In a 10-year follow-up study of all individuals 2 – gastric bypass associated with 40% lower mortality – 56% reduction in death from coronary artery disease – 92% lower death rate from “diabetes” 1. Sjostrom L, et al. N Engl J Med. 2004;351: Adams TD, et al. N Engl J Med. 2007;357:

National Survey Cites Need for New Medical Options for Controlling Type 2 Diabetes Survey of 636 patients with diabetes and 409 primary care physicians in United States Both groups said they lack the tools to successfully manage diabetes over time – 88% of patients and 92% of physicians expressed need for better treatment options 60% of patients are at least somewhat dissatisfied with the weight gain due to their current diabetes medication Both physicians and patients desire new antihyperglycemic therapies that minimize side effects of hypoglycemia and weight gain Physicians may overestimate patients’ fear of needles – 87% of physicians report patients fear needles – 36% of patients expressed such fear Accessed April 9, 2008.

Body Weight (lb) Adapted from Kendall DM, et al. © 2004 International Diabetes Center, Minneapolis, MN. All rights reserved. Years Diabetes Diagnosis Onset Prediabetes (IFG, IGT) Metabolic Syndrome Fasting Glucose Postmeal Glucose Glucose (mg/dL) Obesity, Inactivity, Genetics Relative Function Insulin Resistance Insulin Response Progressive  -Cell Defect (glucose specific) Amylin Response Oral Agents/Incretin Enhancers Basal Insulin Basal/Bolus Insulin Amylin Replacement Natural History of Type 2 Diabetes and Obesity

Weight gain from diabetes medications – Worsens cardiovascular risk factors Especially blood pressure – Is unacceptable for patients Will not choose therapy known to cause weight gain May discourage patients from taking medications Is avoidable with several antihyperglycemic therapies – Metformin – Sitagliptin – Exenatide – Pramlintide Data from bariatric surgery is promising Summary